FDA approves two new treatment regimens:

1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT

2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

FDA approves two new treatment regimens: 1. Acalabrutinib + BR for untreated mantle cell lymphoma patients deemed ineligible for autologous HSCT 2. Sotorasib + panitumumab for KRAS-G12C mutated metastatic colorectal cancer (after chemotherapy, including oxaliplatin and irinotecan)

Acalabrutinb + BR and sotorasib + panitumumab

OncoPharm is a podcast dedicated to all things oncology pharmacy.  Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer.  Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Science

OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.

Share Acalabrutinb + BR and sotorasib + panitumumab

Sign up to save your podcasts

Acalabrutinb + BR and sotorasib + panitumumab

Acalabrutinb + BR and sotorasib + panitumumab

More shows like OncoPharm

JAMA Editors' Summary

NEJM This Week

JAMA Clinical Reviews

The Curbsiders Internal Medicine Podcast

Up First from NPR

Core IM | Internal Medicine Podcast

The ONS Podcast

ASCO Guidelines

Real Life Pharmacology - Pharmacology Education for Health Care Professionals

OncLive® On Air

Harrison's PodClass: Internal Medicine Cases and Board Prep

The Curious Clinicians

WolverHeme Happy Hour

Two Onc Docs

Oncology Brothers: Practice-Changing Cancer Discussions